Defining the boundary between an in-vitro concentration plan and a dosing instruction
On a small UK biotech bench, a concentration plan is a laboratory document. It records the mass of material, the diluent volume, the target concentration for an in-vitro assay, the dilution series, the vehicle control, and the plate-map or sample identifiers that let another researcher repeat the work. It may also note the batch CoA reference, storage conditions before and after reconstitution, and the date the working solution was prepared. That is a very different object from a dosing instruction, which implies administration to a human or animal. The distinction is not semantic housekeeping; it is the line that keeps research-use-only materials inside controlled laboratory and analytical work.
Research Sciences describes its catalogue as research-use-only materials for controlled in-vitro scientific research. Product pages and FAQs state that items are not for human or veterinary use, consumption, administration or clinical application, and are labelled “For Research Use Only – Not for Human Consumption”. The shop presents this as its stated position in line with MHRA guidance; it is not legal advice, and the purchaser remains responsible for lawful use, safe handling, storage, disposal and compliance with relevant UK regulations including COSHH and laboratory safety standards. A small bench often shares templates, calculators and freezer space, so the boundary needs to be visible in the document itself, not only in a senior researcher’s head.
This is where concentration planning can drift. A spreadsheet designed for an in-vitro dilution series may include columns such as “amount”, “volume”, “final concentration” and “aliquot count”. If someone renames “amount” as “dose”, or pastes the calculation into a clinical-style template, the document starts to look like something it must never become. The safer habit is to keep laboratory concentration planning in a controlled template that uses assay language: stock concentration, working concentration, dilution factor, matrix, incubation condition, and analytical endpoint. Avoid fields that imply administration, and avoid carrying over U-100 or U-50 syringe scales unless they are explicitly justified as part of a laboratory delivery step and reviewed under the bench’s COSHH and risk assessments.
The shop’s free peptide reconstitution calculator is described on product pages and in the FAQs for laboratory research use only. It includes mg, mcg, mL, U-100 and U-50 syringe scales and optional IU conversions when a conversion factor is known. Those features do not make the output a dosing instruction. The calculator must not be used for human or veterinary dosing, and any printed calculation should be marked “in-vitro laboratory use only” before it enters a batch record. For a small UK biotech team, the practical control is simple: one document type for assay concentration planning, another for material receipt and storage, and no shared folder where a concentration sheet can be mistaken for a clinical or veterinary instruction.
Documentation habits that keep concentration plans inside the laboratory workflow
Good documentation does not stop a concentration plan from being misread, but it makes misreading less likely. Research Sciences states that Certificates of Analysis are provided for products and that compounds include a CoA covering purity and identity by HPLC, with batch-level analytical verification supporting purity, identity and contaminant screening. The About page describes full-spectrum testing as purity, identity, heavy metals and endotoxin evaluation of submitted samples, while the homepage lists “CoAs Janoshik Analytical Reports”. These are the shop’s published descriptions; researchers should open the CoA that accompanies the specific batch and check the actual document rather than relying on a summary or an old printout.
At bench level, link every concentration plan to the batch record. The label reference format combines SKU code and expiry date, for example BPC10-03/27, and that reference should be quoted when contacting the shop about documentation. Restocked products may carry the same Internal Test Reference as earlier stock, but the FAQs explain that an ITR links to associated sample testing reports; it does not confirm that separate deliveries come from the same production lot or have had separate independent testing. Vial cap colours and other packaging may vary, and cap colour is not an indicator of identity, analytical quality or manufacturing origin. A concentration sheet that records only “the 5mg vial” is therefore weaker than one that records the product listing, batch reference, CoA checked, date opened and storage location.
Storage wording should also stay with the laboratory workflow. The FAQ quick guide says lyophilised peptides should be stored at –20°C or below, sealed with desiccant, protected from moisture, heat and light, with repeated freeze–thaw cycles avoided. Reconstituted peptides are described as less stable and should be stored at 2–8°C for short-term laboratory use. Those statements belong on the bench sheet next to the concentration calculation, because an assay plan is only reproducible if the material history is legible. If a project needs a current catalogue item, the materials manager can check the live listing and Buy peptides for the research catalogue, then open the individual product page and batch CoA before releasing the vial to the bench. That sequence keeps the commercial step subordinate to the research-use-only check and the batch-specific document.
Version control is equally practical. Name files with the project code, assay type and month–year revision, not with words such as “final” or “new”. Keep a controlled calculation template that includes a signature block for preparation and a second-person check. Where the shop describes trace mannitol as an excipient in peptides, record it as a formulation detail relevant to the in-vitro matrix and solubility check, not as a reason to change the document’s purpose. None of these habits require a large quality department. They require the bench to treat the concentration plan as a laboratory record, not as a flexible note that can be adapted into administration language.
Practical scenarios for a small UK bench: audits, shared equipment and materials-manager checks
Consider a small UK biotech team preparing an in-vitro receptor signalling study with a lyophilised research peptide from the catalogue, such as TB-500 5mg or Ipamorelin 5mg. The bench calculates a stock concentration and a dilution series in assay buffer, then records the CoA reference and the storage temperature. A new starter later copies the “final concentration” column into a separate sheet that contains a field called “dose”. Nothing is administered, but the document has crossed a boundary. During an internal audit, the team cannot easily show that the second sheet was only an assay dilution plan. The corrective action is not more arithmetic; it is document design. Remove administration language, rename fields, restrict editing rights, and add a header stating that the material is not for human or veterinary use and that the sheet is for in-vitro laboratory use only.
Shared equipment creates another scenario. A balance, pipette set or plate reader may serve several projects, and a concentration plan may travel with a shared calculator. If the calculator output includes syringe scales, the bench should decide in advance how that output is labelled and stored. The shop’s calculator is for laboratory research use only; it is not a clinical tool and must not be used for human or veterinary dosing. A materials manager can support this by keeping the calculator output with the assay plan, not with purchasing records, and by checking that no concentration sheet is filed alongside invoices or dispatch notes. Fulfilment terms are published separately: the shop states that orders are dispatched the next working day via Royal Mail Tracked 24, which is a Royal Mail estimate rather than a guarantee, and that returns are not accepted once dispatched because of the specialist and perishable nature of the goods. Those details should be reconfirmed on the live site at the time of order, but they do not change the laboratory-only status of the material.
A third scenario is the documentation audit before a project review. The reviewer asks for the concentration plan, the CoA, the storage record and the disposal record. If the plan has been written in dosing language, the team spends time explaining what it did not mean. If the plan has been written as a controlled in-vitro record, the audit is straightforward: the material is research-use-only, the batch CoA has been checked, the storage conditions match the shop’s published guidance and the bench’s own risk assessment, and the concentration values are tied to assay wells rather than to any clinical or veterinary interpretation. For a small UK biotech bench, that is the real advantage of keeping concentration plans separate from dosing instructions. It protects the science, the documentation trail and the compliance position of every researcher who handles the vial.
Toronto indie-game developer now based in Split, Croatia. Ethan reviews roguelikes, decodes quantum computing news, and shares minimalist travel hacks. He skateboards along Roman ruins and livestreams pixel-art tutorials from seaside cafés.